Clinical Trials Logo

Filter by:
NCT ID: NCT04814498 Completed - Clinical trials for Drug Drug Interaction

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Start date: May 3, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers

NCT ID: NCT04814472 Completed - Clinical trials for Relative Bioavailability

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

Start date: May 16, 2021
Phase: Phase 1
Study type: Interventional

A Two-Part, Open-Label, Crossover, Bioavailability Study Comparing Tablet and Oral Solution Formulations of BLD-0409 in Healthy Volunteers

NCT ID: NCT04814108 Suspended - Clinical trials for Uterine Serous Carcinoma

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Start date: July 28, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

NCT ID: NCT04813042 Active, not recruiting - Mental Health Issue Clinical Trials

Determining the Effectiveness of Working Out Dads to Reduce Mental Health Difficulties in Fathers of Young Children

WOD
Start date: June 24, 2021
Phase: N/A
Study type: Interventional

This is an individually randomised trial, where Working Out Dads (WOD) will be delivered as a group intervention. Participants will be randomised to one of two groups: either WOD or usual care.The trial aims to test the effectiveness and cost-effectiveness of WOD, a 6-week week group-based peer support intervention, in reducing fathers' mental health difficulties in early parenthood.

NCT ID: NCT04812925 Active, not recruiting - Clinical trials for Primary Immune Thrombocytopenia

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC+
Start date: November 17, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

NCT ID: NCT04812119 Completed - Clinical trials for CTNNB1 Gene Mutation

Genotype-phenotype Correlations in Children and Adults With CTNNB1 Mutation

Gen-Phe CTNNB1
Start date: March 1, 2021
Phase:
Study type: Observational

The aim of this study is to explore and define the correlations between genotype and phenotype in patients with CTNNB1 mutations as well as monitor and survey the natural history of the CTNNB1 syndrome.

NCT ID: NCT04811560 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of JNJ-75276617 in Participants With Acute Leukemia

Start date: May 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).

NCT ID: NCT04811469 Completed - Clinical trials for Healthy Adult Subjects

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

Start date: May 24, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of CBP-174 after a single oral dose in healthy adult subjects.

NCT ID: NCT04811092 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

HYPERION
Start date: March 18, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.

NCT ID: NCT04811027 Active, not recruiting - HNSCC Clinical Trials

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

TACTI-003
Start date: August 27, 2021
Phase: Phase 2
Study type: Interventional

Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.